EMA Backs Breast Cancer SERD After FDA No Vote

Published Date: 23 May 2026

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Read Full News

Latest News

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Todays Updates

Transforming Perioperative MIBC Care in Community Practice: Navigating Emerging Data, Guideline Changes, and Adverse Event Management Protocols

Transforming Perioperative MIBC Care in Community Practice: Navigating Emerging Data, Guideline Changes, and Adverse Event Management Protocols

Doctors Remain Trusted Sources for Cancer Info in Post-Pandemic Era

Not surprisingly, trust in government health agencies for cancer info has dipped

Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer

Response rates with daraxonrasib ranged from 31% to 37% in previously treated RAS-mutant NSCLC

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

News, features, and commentary about cancer-related issues

More Evidence Ties Microplastics to Lung Cancer

Observational study shows greater microplastic burden in patients with lung malignancy

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

Health news and commentary gathered by MedPage Today staff

9/11's Latest Wave of Cancers, 25 Years On

The health ramifications of the attack persist

Todays Updates

Transforming Perioperative MIBC Care in Community Practice: Navigating Emerging Data, Guideline Changes, and Adverse Event Management Protocols

Transforming Perioperative MIBC Care in Community Practice: Navigating Emerging Data, Guideline Changes, and Adverse Event Management Protocols

Doctors Remain Trusted Sources for Cancer Info in Post-Pandemic Era

Not surprisingly, trust in government health agencies for cancer info has dipped

Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer

Response rates with daraxonrasib ranged from 31% to 37% in previously treated RAS-mutant NSCLC

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

News, features, and commentary about cancer-related issues

More Evidence Ties Microplastics to Lung Cancer

Observational study shows greater microplastic burden in patients with lung malignancy

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

Health news and commentary gathered by MedPage Today staff

9/11's Latest Wave of Cancers, 25 Years On

The health ramifications of the attack persist

Latest News

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

News All Time

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Recommended News For You

EMA Backs Breast Cancer SERD After FDA No Vote

Stereotactic Radiation Linked to Better Brain Mets Outcomes

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

Use of marijuana and alcohol simultaneously is associated with worse outcomes.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

Formaldehyde releasers found in common personal care products used especially by Black and Latina women

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

Recommended Articles For You

The Latest Research on Acute Promyelocytic Leukemia: Advancements in Diagnosis and Therapy  

Integrated Trends in Hematology for Modern Medicine 

Essential Strategies in Hematology for Healthcare Excellence 

Individualized Hematopoietic Reserve Assessment in Blood Disorders 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

2.

Adjunctive Cannabis Extract Improves Nausea-Vomiting Prevention in Cancer Patients

3.

Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.

4.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

5.

Dramatic Increase in Active Surveillance Use for Prostate Cancer

1.

Immune Ecosystem Remodeling Within Solid Tumor Niches

2.

Emerging Methods in Hematology in Clinical Decision-Making

3.

Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment

4.

Nuclear Medicine's Role in Battling Women's Cancers

5.

Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management 

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Blood Clotting Disorders Explained

2.

Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men

3.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

4.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

5.

Should We Use DARA Up Front As First-Line Therapy in MM?


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot